The OJC 54: Cancer Care in the Wake of a Cyber Attack

The Oncology Journal Club Episode 54: Cancer Care in the Wake of a Cyber Attack

Join Eva Segelov, Craig Underhill and Hans Prenen as they chat through the latest papers in this week’s episode of The OJC.

This week Eva talks us through tumour burden and efficacy of immune-checkpoint inhibitor. Hans gets stuck into aligning tumour mutational burden quantification across diagnostic platforms and Craig details the CheckMate 142 Study.

You’ll find out how to deliver Cancer Care in the Wake of a Cyberattack and phew, Hans can relax – Eva tells us that coffee is still good for you.

We’ve also the first guest in our new The Paper That Changed My Practice segment – thanks Merve aka our favourite kiwi, yes it’s Chris Jackson.

Finally, our sincere congratulations to Associate Professor Craig Underhill!

Drop us a line on Twitter with any comments @oncologynewsaus

This Week’s Papers:

1. Dall’Olio FG, et al. Tumour burden and efficacy of immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021 Oct 12. doi: 10.1038/s41571-021-00564-3. Epub ahead of print. PMID: 34642484. Access online here.
2. Vega DM, et al. Aligning Tumor Mutational Burden (TMB) quantification across diagnostic platforms: Phase 2 of the Friends of Cancer Research TMB Harmonization Project. Ann Oncol. 2021 Oct 1:S0923-7534(21)04495-1. doi: 10.1016/j.annonc.2021.09.016. Epub ahead of print. PMID: 34606929. Access online here. 
3. Lenz HJ, et al. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. J Clin Oncol. 2021 Oct 12:JCO2101015. doi: 10.1200/JCO.21.01015. Epub ahead of print. PMID: 34637336. Access online here.

This Week’s Quick Bites:

1. Serna-Blasco R, et al. KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor. ESMO Open. 2021 Oct 1;6(5):100279. doi: 10.1016/j.esmoop.2021.100279. Epub ahead of print. PMID: 34607284; PMCID: PMC8493588. Access online here.
2. Vincenzi B, et al. Adjuvant imatinib in GIST patients harboring exon 9 KIT mutations: results from a multi-institutional European retrospective study. Clin Cancer Res. 2021 Oct 6:clincanres.1665.2021. doi: 10.1158/1078-0432.CCR-21-1665. Epub ahead of print. PMID: 34615721. Access online here.
3. Burke G, . Radiation induced skin reactions during and following radiotherapy: A systematic review of interventions. Radiography (Lond). 2021 Oct 11:S1078-8174(21)00133-4. doi: 10.1016/j.radi.2021.09.006. Epub ahead of print. PMID: 34649789. Access online here.
4. Ades S, et al. Cancer Care in the Wake of a Cyberattack: How to Prepare and What to Expect. JCO Oncol Pract. 2021 Aug 2:OP2100116. doi: 10.1200/OP.21.00116. Epub ahead of print. PMID: 34339260. Access online here.
5. Hall WA, et al. Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. J Clin Oncol. 2021 Oct 8:JCO2101220. doi: 10.1200/JCO.21.01220. Epub ahead of print. PMID: 34623894. Access online here.

Amazing Paper of the Week:

Eva Niezen S, et al. Coffee consumption is associated with lower liver stiffness: a nationally representative study. Clin Gastroenterol Hepatol. 2021 Oct 6:S1542-3565(21)01057-0. doi: 10.1016/j.cgh.2021.09.042. Epub ahead of print. PMID: 34626832. Access online here.

 Twitter Account of the Week:

@DrNadiaChaudhri

Nadia Chaudhri Obituary by Verity Stevenson. CBC News. Posted: Oct 06, 2021 6:01 PM ET. 

Other Episodes Mentioned:

The OJC Episode 32: When the Oncologist Gets Cancer featuring Heidi Probst

This Week’s Team:

Professor Eva Segelov

Eva Segelov

Professor Eva Segelov is a Medical Oncologist and is Director of Oncology at Monash University and Monash Health, Melbourne, Victoria, previously Senior Medical Oncologist at St Vincent’s Hospital, St Vincent’s Private Hospital and St Vincent’s Clinic and Associate Professor of Medicine, University of New South Wales.

Eva has an interest in academic clinical trials in GI and breast cancer and has been a member of the AGITG since 2003. She has clinical trials expertise, links with national and international trials groups, and extensive experience with adult medical education. You can find Eva on Twitter here: @profevasegelov

Professor Hans Prenen

Hans Prenen

Professor Hans Prenen is a medical oncologist and head of the phase 1 – early clinical trials unit at the Antwerp University Hospital in Belgium. He is a member of several scientific organisations, published many scientific oncology papers in prestigious journals and is regularly invited for lectures at national and international meetings.  His interests are clinical trials and translational research with a focus on digestive oncology. You can find Hans on Twitter here: @HPrenen

Associate Professor Craig Underhill

Craig Underhill

Associate Professor Craig Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He completed medical oncology training in Melbourne and worked as the Senior Clinical Research Registrar at Guy’s Hospital, London.

In 1998 arrived in Albury-Wodonga and established a medical oncology practice and clinical trials unit which has developed expertise and infrastructure to ensure the initiation of high quality trials. The research Unit lead by Dr Underhill has twice been awarded NSW Premier’s Award for Innovation in Cancer Clinical Trials, the inaugural award in 2009 and then again in 2012.

Dr Underhill is the VCCC Regional Oncology Lead and advocates for the increased access to clinical trials for regional Victorians and leads the VCCC teletrials program. You can find Craig on Twitter here: @CraigUnderhill 

Merve AKA Dr Christopher Jackson

MERVE… Chris Jackson

Chris Jackson is a Medical Oncologist with special interest in gastrointestinal cancers, melanoma and urological cancers. Chris holds a national role in the research and management of colorectal cancer.

Chris is currently the clinical leader for oncology research at Dunedin Hospital, and has strong links with cancer trials within New Zealand. In 2015 Chris was appointed as Medical Director of the Cancer Society of New Zealand.

Chris was born and raised in Otago and is strongly committed to the region. He is a cofounder of Mercy Cancer Care, with Mercy Hospital in 2011 ensuring that patients affected by cancer are offered a full range of systemic treatments that may not otherwise be available.

Rachael Babin

Rachael Babin is Editor-in-Chief of The Oncology Newsletter, Publisher of Oncology News Host of The Oncology Podcast and Producer of The Oncology Journal Club. For regular oncology updates for healthcare professionals, please subscribe to The Oncology Newsletter.

With thanks to Eva Segelov, Craig Underhill, Hans Prenen and Graham Knowles.

Connect with us on Twitter @OncologyNewsAus